Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
bioAffinity TechnologiesBIAFW +62.71%44 14-Day RSI is 65.21 as of Sep. 11, 2026. GuruFocus rates BIAFW with a GF Score™ of 44/100. The stock has 3 warning signs investors should review. Among 218 Medical Diagnostics & Research companies, bioAffinity Technologies ranks worse than 67.43% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
bioAffinity Technologies 14-Day RSI Related Terms
BIAFW vs ISPC, IVRO, IDTA: 14-Day RSI Comparison
For the Diagnostics & Research subindustry, bioAffinity Technologies's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
bioAffinity Technologies 14-Day RSI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where bioAffinity Technologies's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
bioAffinity Technologies (BIAFW) has a 14-Day RSI of 65.21 as of Sep. 11, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on bioAffinity Technologies and its competitors. According to the industry distribution chart, bioAffinity Technologies ranks #147 out of 218 companies in the Medical Diagnostics & Research industry, placing it in the top 67.4%.
Is bioAffinity Technologies' 14-Day RSI too high?
bioAffinity Technologies' current 14-Day RSI is 65.21. The Medical Diagnostics & Research industry median 14-Day RSI is 47.69. bioAffinity Technologies' value of 65.21 is 36.7% above this industry median. Based on the distribution chart, bioAffinity Technologies ranks #147 out of 218 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, bioAffinity Technologies has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does bioAffinity Technologies' 14-Day RSI compare to ISPC and IVRO?
According to the Medical Diagnostics & Research industry distribution chart, bioAffinity Technologies ranks #147 out of 218 companies for 14-Day RSI. This places bioAffinity Technologies in the lower half of its industry. The industry median 14-Day RSI is 47.69. bioAffinity Technologies' value of 65.21 is 36.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Diagnostics & Research company?
The median 14-Day RSI among Medical Diagnostics & Research companies is 47.69, based on 218 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. bioAffinity Technologies's current 14-Day RSI of 65.21 is 36.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on bioAffinity Technologies and its competitors. For the Medical Diagnostics & Research industry, the median 14-Day RSI is 47.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. bioAffinity Technologies's current 14-Day RSI is 65.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is bioAffinity Technologies stock overvalued right now?
bioAffinity Technologies (BIAFW) has a current 14-Day RSI of 65.21. The current 14-Day RSI is 65.21 and 36.7% above the Medical Diagnostics & Research industry median of 47.69. bioAffinity Technologies' overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For bioAffinity Technologies (BIAFW), the current 14-Day RSI is 65.21 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
44GF Score
Get the complete analysis for BIAFW
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIAFW has been successfully added to your 
